- Home
- OZ vs HRTX Comparison
OZ vs HRTX Comparison
Compare OZ & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OZ
- HRTX
- Stock Information
- Founded
- OZ 2020
- HRTX 1983
- Country
- OZ United States
- HRTX United States
- Employees
- OZ N/A
- HRTX 126
- Industry
- OZ
- HRTX Biotechnology: Pharmaceutical Preparations
- Sector
- OZ
- HRTX Health Care
- Exchange
- OZ Nasdaq
- HRTX Nasdaq
- Market Cap
- OZ 271.6M
- HRTX 240.3M
- IPO Year
- OZ N/A
- HRTX 1987
- Fundamental
- Price
- OZ $78.01
- HRTX $1.59
- Analyst Decision
- OZ
- HRTX Strong Buy
- Analyst Count
- OZ 0
- HRTX 3
- Target Price
- OZ N/A
- HRTX $5.67
- AVG Volume (30 Days)
- OZ 5.3K
- HRTX 6.2M
- Earning Date
- OZ 01-01-0001
- HRTX 11-12-2024
- Dividend Yield
- OZ N/A
- HRTX N/A
- EPS Growth
- OZ N/A
- HRTX N/A
- EPS
- OZ N/A
- HRTX N/A
- Revenue
- OZ $2,092,000.00
- HRTX $137,737,000.00
- Revenue This Year
- OZ N/A
- HRTX $13.10
- Revenue Next Year
- OZ N/A
- HRTX $18.76
- P/E Ratio
- OZ N/A
- HRTX N/A
- Revenue Growth
- OZ N/A
- HRTX 12.13
- 52 Week Low
- OZ $42.75
- HRTX $1.04
- 52 Week High
- OZ $80.88
- HRTX $3.93
- Technical
- Relative Strength Index (RSI)
- OZ 65.09
- HRTX 50.28
- Support Level
- OZ $77.93
- HRTX $1.53
- Resistance Level
- OZ $80.88
- HRTX $1.88
- Average True Range (ATR)
- OZ 1.87
- HRTX 0.17
- MACD
- OZ 0.20
- HRTX 0.01
- Stochastic Oscillator
- OZ 82.01
- HRTX 47.67
About OZ Belpointe PREP LLC Units
Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.